Biotechnology

Filter

Current filters:

None

Popular Filters

51 to 75 of 2563 results

Ember Therapeutics to merge with Mariel Therapeutics

Ember Therapeutics to merge with Mariel Therapeutics

12-03-2015

Ember Therapeutics, a US biotech company focused on obesity and diabetes therapies, is to merge with…

BiotechnologyEmber TherapeuticsMariel TherapeuticsMergers & AcquisitionsUSA

WuXi PharmaTech to build new cell therapy manufacturing facility in USA

12-03-2015

Shanghai, China-headquartered WuXi PharmaTech announced today that it will soon begin construction of…

BiotechnologyOncologyProductionUSAWuXi PharmaTech

23andMe creates new therapeutics group and apoints Genentech's Richard Scheller to lead

23andMe creates new therapeutics group and apoints Genentech's Richard Scheller to lead

12-03-2015

Privately-held genomics and biotech company 23andMe has created a new therapeutics group, and appointed…

23andMeAnne WojcickiBiotechnologyBoardroomGenentech

Spain to reduce the prices of new biosimilars by up to 30%

Spain to reduce the prices of new biosimilars by up to 30%

12-03-2015

After months of uncertainty, the Spanish Ministry of Health has announced its new policy for the biosimilars…

BiosimilarsBiotechnologyinfliximabPoliticsPricingSpain

AusBiotech says EMDG provides critical support for biotech

AusBiotech says EMDG provides critical support for biotech

12-03-2015

Trade group AusBiotech has submitted to the review of the Export Market Development Grants (EMDG) to…

AusBiotechAustraliaBiotechnologyFinancialMarkets & Marketing

AgeneBio’s GB101 Alzheimer’s candidate restored brain function to pre-disease level

AgeneBio’s GB101 Alzheimer’s candidate restored brain function to pre-disease level

11-03-2015

US privately-held biotech firm AgeneBio says that results from a Phase II clinical published in NeuroImage:…

AgeneBioBiotechnologyGB101NeurologicalResearch

Egalet to file NDA for abuse-deterrent morphine in 4th-qtr

Egalet to file NDA for abuse-deterrent morphine in 4th-qtr

11-03-2015

Shares of US biotech firm Egalet Corp rose 3.65% to $14.48 after it said it plans to file a New Drug…

BiotechnologyEgalet CorpEgalet-001NeurologicalRegulationResearchUSA

Second $50M milestone for Ophthotech under Fovista deal with Novartis

11-03-2015

US biotech firm Ophthotech says it has achieved a second $50 million enrollment milestone from Swiss…

BiotechnologyFinancialFovistaNovartisOphthalmicsOphthotechResearch

NICE says ‘yes’ to new blood cancer drug from Roche

NICE says ‘yes’ to new blood cancer drug from Roche

11-03-2015

Patients in England and Wales with chronic lymphocytic leukemia (CLL) could soon benefit from Gazyvaro…

BiotechnologyGazyvaroOncologyPricingRegulationRocheUK

FDA approves Unituxin for high-risk neuroblastoma

FDA approves Unituxin for high-risk neuroblastoma

10-03-2015

The US Food and Drug Administration today approved US biotech firm United Therapeutics’ Unituxin (dinutuximab)…

BiotechnologyOncologyRegulationUnited TherapeuticsUnituxinUSA

CTI BioPharma and Baxter’s pacritinib meets primary endpoint in myelofibrosis trial

CTI BioPharma and Baxter’s pacritinib meets primary endpoint in myelofibrosis trial

10-03-2015

US biotech firm CTI BioPharma saw its shares rise 6.4% to $2.82 on Monday, after the company, along with…

Baxter InternationalBiotechnologyCTI BioPharmaOncologypacritinibResearch

Unanimous FDA advisory panel backing for KYTHERA’s ATX-101

Unanimous FDA advisory panel backing for KYTHERA’s ATX-101

10-03-2015

US biotech firm KYTHERA Biopharmaceuticals said yesterday that the US Food and Drug Administration's…

ATX-101BayerBiotechnologyDermatologicalsKYTHERA BiopharmaceuticalsRegulationUSA

EMD Serono and Opexa amend deal on MS drug candidate Tcelna

EMD Serono and Opexa amend deal on MS drug candidate Tcelna

09-03-2015

EMD Serono, the US biopharmaceutical division of Germany’s Merck KGaA has amended its agreement with…

BiotechnologyEMD SeronoFinancialLicensingMerck KGaANeurologicalOpexa TherapeuticsResearchTcelna

Arrowhead acquires Novartis' RNAi R&D portfolio

Arrowhead acquires Novartis' RNAi R&D portfolio

07-03-2015

USA-based nano-medicine developer Arrowhead Research Corp revealed on Thursday that it has acquired Swiss…

Arrowhead ResearchArrowhead Research CorpBiotechnologyLicensingNovartis

Targacept and Catalyst Biosciences agree to merge

Targacept and Catalyst Biosciences agree to merge

07-03-2015

Targacept and fellow USA-based Catalyst Biosciences, a privately held biopharmaceutical firm, have entered…

BiotechnologyCatalyst BiosciencesHematologyMergers & AcquisitionsTargacept

Adocia opens US subsidiary and appoints Simon Bruce and Stephen Daly

Adocia opens US subsidiary and appoints Simon Bruce and Stephen Daly

06-03-2015

French biotech company Adocia has created a US subsidiary, Adocia Incorporated, and appointed Simon Bruce…

AdociaAdocia IncorporatedBiotechnologyBoardroomUnited States

Sandoz’s Zarxio first biosimilar to be approved under new FDA pathway

Sandoz’s Zarxio first biosimilar to be approved under new FDA pathway

06-03-2015

Sandoz, the generics unit of Swiss pharma giant Novartis, today received approval from the US Food and…

AmgenBiosimilarsBiotechnologyNeupogenNovartisOncologyRegulationSandozUSAZarxioZarzio

Megafunds could solve biotech financing and unlock new orphan drug funding

Megafunds could solve biotech financing and unlock new orphan drug funding

06-03-2015

A new financing technique could reduce the risk associated with investing in the treatment of new diseases…

BiotechnologyFinancialHealthMedicineNational Center for Advancing Translational Studies

Gates Foundation makes $52 million investment in CureVac

Gates Foundation makes $52 million investment in CureVac

06-03-2015

The Bill & Melinda Gates Foundation has committed to invest $52 million in private biopharma company…

BiotechnologyBusiness FinanceCureVacHealth Medical PharmaUnited States

Spero Therapeutics gains rights to novel anti-infectives developed at HZI

Spero Therapeutics gains rights to novel anti-infectives developed at HZI

06-03-2015

Ascenion, the technology transfer partner of Germany’s Helmholtz Center for Infection Research (HZI),…

Antibiotics and Infectious diseasesBiotechnologyLicensingResearchSpero Therapeutics

AOP Orphan updates on Phase III trial PROUD-PV applying ropeginterferon

06-03-2015

Austria-based rare diseases specialist AOP Orphan Pharmaceuticals has completed recruitment for its Phase…

AOP Orphan PharmaceuticalsBiotechnologyPharmaEssentiaRare diseasesResearchropeginterferon alfa 2b

51 to 75 of 2563 results

Back to top